The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.
A. Biondo
No relevant relationships to disclose
T. A. Yap
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
L. Yan
Employment or Leadership Position - Merck
Stock Ownership - Merck
A. Patnaik
Research Funding - Merck
I. Fearen
Employment or Leadership Position - Merck
Stock Ownership - Merck
R. D. Baird
No relevant relationships to disclose
K. P. Papadopoulos
Research Funding - Merck
L. M. Delgado
Stock Ownership - Merck
A. Taylor
Employment or Leadership Position - Merck
Stock Ownership - Merck
L. Lupinacci
Employment or Leadership Position - Merck
Stock Ownership - Merck
S. C. Blackman
Stock Ownership - Merck
S. Decordova
No relevant relationships to disclose
M. Tall
No relevant relationships to disclose
S. Heaton
No relevant relationships to disclose
M. D. Garrett
Research Funding - Merck
D. Sullivan
Research Funding - Merck
J. S. De Bono
Employment or Leadership Position - The Institute of Cancer Research
Consultant or Advisory Role - AstraZeneca; Genentech; Merck
Honoraria - AstraZeneca; Genentech; Merck; Novartis
Research Funding - AstraZeneca (I)
A. W. Tolcher
Consultant or Advisory Role - AbGenomics International; Abraxis BioScience; Actavis; Adnexus; Ambit BioSciences; Amgen; ARIAD; Arresto; Astellas Pharma; Bayer; BIND Biosciences; Biogen Idec; Chemokine; Curis; Dendreon; Dicerna; Endo Pharmaceuticals; Enzon; Exelixis; FivePrime; Genentech; Geron; GlaxoSmithKline; HUYA Bioscience International; Insert Therapeutics; Intellikine; Johnson & Johnson; Merck; Micromet; Nektar; Novartis; Ortho Biotech; Otsuka; Pfizer; PPD Development; ProNAi; Regeneron; Sanofi ; Santaris; Spectrum Pharmaceuticals; SuperGen; Symphogen; Vaccinex; Veeda Oncology
Research Funding - Abbott Laboratories; Adnexus; Ambit BioSciences; Amgen; ArQule; Array BioPharma; Arresto; Astellas Pharma; AVEO; Azaya Therapeutics; Bayer; Biogen Idec; BiPar Sciences; Bristol-Myers Squibb; Calando; Centocor Ortho Biotech; Coronado Biosciences; Cougar Biotechnology; Cougar Biotechnology; Curis; Cyclacel; Cylene; Daiichi Sankyo; Dendreon; Enzon; Exelixis; FivePrime; Genentech; Genta; GlaxoSmithKline; Hana BioSciences; Immunogen; Lilly; Merck; Merrimack; MethylGene; Millennium; Myrexis; Nektar; Nerviano; Novartis; OncoMed; Onyx; Pfizer; PharmaMar; Proacta; ProNAi; Provia Biologics; Roche; Sanofi ; Schering-Plough; Spectrum Pharmaceuticals; SuperGen; Symphogen; Vaccinex